Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Surmodics Inc reports significant gains in medical device sales and operational achievements, despite challenges in the IVD segment.
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.